PCRX earnings analysis
What we found in PCRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Pacira delivered 6% year-over-year Q2 revenue growth to $192.399 million, driven by EXPAREL and ZILRETTA, while GAAP diluted EPS improved to $0.12. However, operating margin fell to approximately 2.2% from 4.7% a year earlier, reflecting higher development and operating costs plus $5.931 million of iovera° divestiture expense. Strong six-month operating cash flow of $83.140 million and $251.0 million of cash and investments support liquidity, but lost future iovera° revenue, tariff pressure, and reliance on uncertain divestiture milestones temper the outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and GAAP EPS improved
- Q2 revenue was $192.399 million, up 6% from $181.099 million in Q2 2025 and 8.7% from $177 million in Q1 2026. GAAP diluted EPS improved to $0.12 from a $0.11 loss in Q2 2025 and $0.07 in Q1 2026.
- Core product sales grew
- Core franchises both expanded: EXPAREL revenue rose 3% to $147.823 million on 4% gross-vial-volume growth, while ZILRETTA revenue increased 4% to $32.648 million, supported by 2% kit-volume growth and a 2% net-price increase.
- Cash conversion strengthened
- Six-month operating cash flow increased $35.7 million year over year to $83.140 million. With $4.110 million of six-month capex, derived free cash flow was $79.030 million and capex was approximately 1.1% of six-month revenue of $369.775 million.
- Liquidity and working capital remain strong
- Liquidity was substantial at June 30, with $251.0 million of cash, cash equivalents and available-for-sale investments and $493.2 million of working capital. Cash and cash equivalents increased $47.330 million during the first six months.
- Access and pipeline catalysts advanced
- UnitedHealthcare added separate outpatient reimbursement for EXPAREL, bringing separately reimbursed access to approximately 150 million covered lives. Management also completed enrollment of 49 patients in ASCEND Part A and expects topline data before year-end 2026.
- iovera° sale added near-term cash
- The iovera° divestiture closed July 31 and generated $73.6 million of cash after purchase-price adjustments, versus a stated $70.0 million upfront payment. The deal can also provide up to $70.0 million of contingent consideration through December 31, 2031.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating-margin compression
- Operating margin contracted to approximately 2.2% ($4.267 million of operating income) from 4.7% in Q2 2025 and 3.9% in Q1 2026. Q2 included $5.931 million of divestiture-related expense, while R&D rose 7% to $30.243 million and SG&A rose 4% to $91.809 million.
- Tariffs threaten gross margin
- Management expects tariffs to negatively affect gross margin. Relevant exposure includes 15% tariffs on certain imports from the E.U. and Switzerland and a 10% tariff on certain U.K. imports, where finished dosage manufacturing occurs.
- New risk: iovera° divestiture execution
- The newly added 10-Q risk factor states Pacira may not realize the expected iovera° divestiture benefits. iovera° generated $6.806 million of Q2 revenue, which will cease after the July 31 closing, and the company may not receive up to $70.0 million in contingent milestones.
- New risk: contingent milestones uncertain
- A second new risk factor highlights uncertainty around Zimmer-controlled milestone payments: the $18.5 million, $23.5 million, and $28.0 million payments require annual iovera° revenue thresholds of $50.0 million, $60.0 million, and $70.0 million, respectively, through December 31, 2031.
- Tax benefit supported reported EPS
- GAAP earnings benefited from a $6.4 million discrete U.K. deferred-tax benefit in Q2. The reported $0.12 GAAP EPS therefore includes a material non-operating tax benefit alongside only $2.555 million of pretax income.
- Leverage and floating-rate exposure
- Debt totaled $368.5 million at June 30, comprising $287.5 million of 2.125% 2029 convertible notes and $81.0 million drawn on the revolver. The revolver's approximate all-in rate was 6.72%, and a 100-basis-point rate increase would add about $0.8 million of annual interest expense.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.12
- Gross margin
- 77.0%
- Operating margin
- 2.2%
- Segment
- EXPAREL: $147.823 million, up 3% year over year
- Segment
- ZILRETTA: $32.648 million, up 4% year over year
- Segment
- iovera°: $6.806 million, up 22% year over year; divested July 31, 2026
- Segment
- Bupivacaine liposome injectable suspension: $3.216 million, up more than 100% year over year
- Segment
- Royalty revenue: $1.906 million, versus $0.752 million a year earlier
What they said about what is next.
The 10-Q does not provide explicit quantitative revenue or EPS guidance. Management expects PCRX-201 ASCEND Part A topline 12-month data before the end of 2026, expects to initiate a PCRX-2002 Phase 2 bunionectomy program later in 2026, and expects LG Chem partnership revenue to begin in 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 30, 2026
- Pacira BioSciences reported Q1 2026 revenues of $177.4 million, reflecting a 5% increase from $168.9 million a year ago, while EPS was $0.07, significantly underperforming the consensus estimate of $0.52. The company…
- 10-K · February 26, 2026
- Pacira reports modest topline growth to $727.0M for the year (sum of 2025 quarters) with EXPAREL remaining the primary driver at $575.1M (79% of revenues). The company launched its 5x30 strategy in January 2025 (goal:…
- 10-Q · August 5, 2025
- Pacira reported Q2 revenue of $181.1M (up from $178.0M in Q2 2024) with a gross margin around 77.4% and operating margin of ~4.7%, but swung to a GAAP net loss of $4.8M (loss per diluted share $0.11) versus net income…
- 10-K · February 27, 2025
- Pacira’s 10-K (year ended December 31, 2024) emphasizes a transition to a broader musculoskeletal/biopharma strategy via the January 2025 “5x30” plan while continuing to rely on three commercial products (EXPAREL,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PCRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever